10:09 AM EDT, 08/01/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday its phase 3 clinical trial showed that Tirzepatide demonstrated statistically significant improvements in the reduction of heart-failure risks as well as improvements in heart-failure symptoms and physical limitations compared with a placebo.

Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist that was approved by the US Food and Drug Administration as Zepbound for adults with obesity and as Mounjaro for adults with type 2 diabetes.

Price: 831.82, Change: +27.55, Percent Change: +3.43